1. Canada Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
SureNano Science Ltd

SureNano Science Ltd

0.09
USD
+0.00
(-0.11%)
-0.01EPS
4.62MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
-0.06
-0.02
-0.01
- -
-0.02
-0.02
Free Cash Flow per Basic Share
- -
-0.03
-0.02
-0.01
-0.01
-0.02
-0.02
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.04
0.03
0.01
- -
- -
0.13
0.12
Tangible Book Value per Share
0.04
0.03
0.01
- -
- -
0.02
0.02
Basic Weighted Avg Shares
20
20
21
21
21
27
33
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
-6,209.71
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-1
- -
- -
- -
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-6,214.79
- -
- -
- -
- -
- -
Working Capital
1
1
- -
- -
- -
1
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
Total Equity
1
1
- -
- -
- -
5
5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-139.88
-84.43
- -
- -
- -
- -

Capital Structure

CAD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
34
42
42
Market Capitalization
5
12
7

Working Capital

CAD

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
1
1
1
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1,330.61%
-6,749.02%
Free Cash Flow
- -
- -
202.58%
Net Income, GAAP
- -
- -
826.27%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
0.01
- -
2026
- -
- -
-0.01
- -
-0.02
2027
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Charles MaLette
Full Time Employees
- -
Sector
Health technology
Industry
Pharmaceuticals: other
Address
1500 – 800 West Pender Street Vancouver BC Canada V6C 2V6
IPO Date
Dec 20, 2021
Website
surenano.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
SureNano Science Ltd. engages in the sale and distribution of nanotechnology-based emulsifying compounds primarily for cannabis, hemp, and other oil-soluble active ingredient applications in Canada and the United States. The company offers its flagship SureNano surfactant, a ready-to-mix food-grade blend of six natural, GRAS-approved ingredients that serves as the base for high-performance nano-emulsions achieving 40-50 nanometer droplet sizes; these enable homogeneous, stable water-dispersible products with enhanced bioavailability, clarity, taste modulation via Free Flavor technology, full entourage effect preservation, and lymphatic pathway digestion to bypass liver metabolism for beverages, sprays, edibles, topicals, tinctures, and more, manufactured under license by Caldic International to global GMP standards. SureNano Science Ltd., founded in 2021 and headquartered at #350-1650 West 2nd Avenue, Vancouver, BC V6J 1H4, Canada, provides complementary services including supply chain support, facility setup packages with equipment procurement and training, and knowledge transfer for client production. In November 2025, the company entered a non-binding letter of intent to acquire GlucaPharm Inc., advancing due diligence on its GLP-1 drug development assets including the GEP-44 triple antagonist for obesity and diabetes treatments; it concurrently launched a private placement for up to $1,250,000 to fund operations, market exploration, and such strategic opportunities while holding exclusive distribution rights for SureNano in Canada and Colorado, USA.

Company News

Company News APIChatGPT

  • globenewswire.com

    SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advancing a Differentiated Next-Gen GLP-1 Platform